scispace - formally typeset
S

Stanley W. Ashley

Researcher at Brigham and Women's Hospital

Publications -  527
Citations -  31560

Stanley W. Ashley is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Breast cancer & Pancreatitis. The author has an hindex of 83, co-authored 498 publications receiving 29893 citations. Previous affiliations of Stanley W. Ashley include West Los Angeles College & Creighton University.

Papers
More filters
Journal ArticleDOI

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

O. Abe, +412 more
- 14 May 2005 - 
TL;DR: The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis.
Journal ArticleDOI

Overview of the main outcomes in breast-cancer prevention trials.

TL;DR: Although tamoxifen cannot yet be recommended as a preventive agent (except possibly in women at very high risk with a low risk of side-effects), continued follow-up of the current trials is essential for identification of a subgroup of high-risk, healthy women for whom the risk-benefit ratio is sufficiently positive.
Journal ArticleDOI

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.

TL;DR: Findings indicate that oral clodronate has a beneficial effect on the skeletal morbidity associated with breast cancer and should be considered as antiosteolytic therapy in affected patients.
Journal ArticleDOI

Laparoscopic Cholecystectomy The New 'Gold Standard'?

TL;DR: Laparoscopic cholecystectomy is regarded as the "gold standard" therapy for management of symptomatic cholelithiasis.
Journal ArticleDOI

Do Patients With Weight Loss Have a Worse Outcome When Undergoing Chemotherapy for Lung Cancers

TL;DR: Weight loss as a symptom of lung cancer predicts for toxicity from treatment and shorter survival and an independent predictor of progression-free survival in patients with SCLC and NSCLC.